Latest Oculis News & Updates

See the latest news and media coverage for Oculis. We track all announcements, press releases, and industry mentions in real time, all in one place.

Oculis

Clinical biopharmaceutical company

oculis.com

Headquarters: Lausanne, Switzerland
Founded year: 2017
Company type: Public company
Number of employees: 80–200
Industry: Pharmaceuticals

Last updated October 19

Latest news about Oculis

In short: Oculis advanced Privosegtor, completed PREDICT-1 randomization, and reported biomarker data after its OCS-01 trials failed.

Company announcements

August 24 Oculis

Oculis begins treating first patient in PIONEER-1 trial

FDA granted Special Protocol Assessment for Privosegtor. This follows positive Phase 2 ACUITY data towards a first-in-class optic neuritis treatment.

August 10 Oculis

Oculis acquires Privosegtor assets from Accure Therapeutics

The transaction includes a $3.8 million upfront payment and share consideration, strengthening Oculis' neuro-ophthalmology pipeline ahead of Phase 3 trials

August 6 Oculis

Oculis reports Q2 2026 financial results and updates pipeline progress

Cash reserves reach $282.3 million as Privosegtor enters Phase 3 trials while Licaminlimab enrollment exceeds 45%. The company pivots to neuro-ophthalmology with strong balance sheet support.

August 3 Oculis

Oculis receives positive FDA feedback for Privosegtor

The FDA supports the regulatory pathway for treating acute multiple sclerosis relapses with Privosegtor. Oculis plans to submit a new Investigational New Drug application in Q4 2026.

Media coverage

October 19 Marketscreener

Oculis Holding AG completes randomization in the genotype-based registration study PREDICT-1 on licaminlimab for dry eye disease

Oculis Holding AG has completed randomization in the genotype-based registration study PREDICT-1 on licaminlimab, with the aim of enabling precision medicine for dry eye disease...

September 17 Seeking Alpha

Oculis Holding AG: Navigating Through Major Trial Setback

Oculis Holding AG remains a clinical-stage biopharma focused on ophthalmic diseases, with a $650M market cap. Click to read my analysis on OCS.

August 15 Markets Insider

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Company pivot to neuro-ophthalmology continues with Privosegtor positioned as lead late-stage asset through the registrational PIONEER program with expansion potential in acute multiple sclerosis (MS...

August 15 Healio

Oculis to acquire development, commercial rights for optic neuritis candidate

Please provide your email address to receive an email when new articles are posted on . Oculis will acquire all worldwide rights to privosegtor from...

Never miss news about Oculis

Track Oculis and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Oculis competitors & trending companies

Browse news for competitors to Oculis and other trending companies.